When choosing genes to include in a gene panel, care should be taken to select genes which have both clinical validity and clinical utility for the phenotype of concern.
The likelihood of identifying a variant of uncertain significance increases as the number of genes included in a panel increases.
Genes associated with prostate cancer |
Gene^ |
Comments |
ATM |
Prostate cancer risk increased but not well quantified
An eviQ risk management protocol has been developed for non-prostate related cancers^^
|
BRCA1 |
Prostate cancer risk may be increased but not well quantified
An eviQ risk management protocol has been developed
Potential treatment implications for affected individuals^^^
|
BRCA2 |
Increased risk of prostate cancer, associated with earlier onset, higher grade, higher stage and worse prognosis
An eviQ risk management protocol has been developed
Potential treatment implications for affected individuals^^^
|
HOXB13 G84E (c.251G>A) |
Increased risk of prostate cancer#
An eviQ risk management protocol has been developed
|
PALB2 |
Prostate cancer risk may be increased but not well quantified
An eviQ risk management protocol has been developed for non-prostate related cancers^^
|
^ Genes are listed alphabetically; the order of listing does not give any indication of the clinical validity/utility of testing the gene.
^^ Gene-specific risk management guidelines for prostate cancer have not been developed by eviQ due to insufficient evidence.
^^^ Potential treatment implications will vary between patients and need to be discussed with the treating specialist.
# From one publicationr, based on early data from a founder population and may be an overestimation of risk.